Cite

    Thomas B. Casale et al.. “Oral corticosteroid-sparing effects of mepolizumab in severe eosinophilic asthma: evidence from randomized controlled trials and real-world studies.” Therapeutic advances in respiratory disease, vol. 16, 2022, p. . http://access.bl.uk/ark:/81055/vdc_100169888854.0x000060